Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Infliximab for treatment-refractory transverse myelitis following immune therapy and radiation

Abstract Background Neurologic toxicities with immune therapy are rare, but can cause devastating and often permanent injury when they occur. Although there is increasing interest in the potential synergism between immune therapy and radiation, it is possible that such combinations may lead to a gre...

Full description

Bibliographic Details
Main Authors: Victoria A. Chang, Daniel R. Simpson, Gregory A. Daniels, David E. Piccioni
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Transverse myelitis
Infliximab
Immune-related adverse events
Checkpoint inhibitor
Radiation
Online Access:http://link.springer.com/article/10.1186/s40425-018-0471-2

Internet

http://link.springer.com/article/10.1186/s40425-018-0471-2

Similar Items